论文部分内容阅读
维生素D及其代谢产物,在治疗代谢性骨病及钙、磷代谢障碍(佝偻病及骨软化症)以及肾性骨营养不良中,有其特殊地位。但在最常见的代谢性骨病(骨质疏松症)的发病机理中的意义,近十多年来尚有争论。这是由于骨质疏松患者的骨活检中,较少见到较显著的骨矿化作用障碍(类骨质变化),因而认为维生素D缺乏尚不能视为骨质疏松发生的病因。在八十年代早期多组研究均未能显示维生素D的治疗作用,使应用钙三醇(1,25-二羟D_3,活性最强的维生素D_3代谢产物)治疗骨质疏松症的热潮消退了,在欧洲已几乎不用于治疗骨质疏松症。
Vitamin D and its metabolites, in the treatment of metabolic bone disease and calcium and phosphorus metabolism disorders (rickets and osteomalacia) and renal osteodystrophy, has its special status. However, the significance of the pathogenesis of the most common metabolic bone disease (osteoporosis) has been debated for more than a decade. This is due to osteoporosis in patients with bone biopsy, less to see the more significant bone mineralization disorders (bone-like changes), and therefore that vitamin D deficiency can not yet be considered as the cause of osteoporosis. In the early 1980s, many groups of studies failed to show the therapeutic effect of vitamin D, and the craze for the treatment of osteoporosis subsided with calcitriol (1,25-dihydroxy D 3, the most active vitamin D 3 metabolite) , Has almost no use in Europe for the treatment of osteoporosis.